Table 3.
Main clinical studies ongoing in pancreatic cancer of last 5 years discussed in the text.
| Drug’s Name | Sample Size | Combined Regimens | Response Rate | Objective Response Rate | Overall Survival (Months) | Progression Free Survival (Months) | Median Survival Time | Didease Control Rate | Time to Progression |
|---|---|---|---|---|---|---|---|---|---|
| Sorafenib [58] | 71 | Gemcitabine plus or not Sorafenib in patients with LDH values under or above the cut-off | 10.7 vs. 5.9 | 5.2 vs. 2.7 | |||||
| Elpamotide [73] | 153 | Gemcitabine plus or not Elpamotide | No significative | 3.71 vs. 3.75 | 8.36 vs. 8.54 | 59.6% vs. 60.4% | |||
| Everolimus [75] | 27 | Everolimus in combination with escalating low-dose gemcitabine | 13% | ||||||
| Sorafenib [59] | 25 | Gemcitabine-based chemoradion therapy plus or not Sorafenib | 12.6 in evaluable patients; 11.5 in intent to treat patients; 21.6 in patients with VEGF-A -2578 AA, -1498 CC genotypes; 14.7 in patients with VEGF-A -1154 AA genotype |
10.6 in evaluable patients; 9.9 in intent to treat patients |
10.7 in evaluable and in intent to treat patients | ||||
| Bevacizumab [116] | 163 | Gemcitabine plus Bevacizumab in patient with related hypertension (B-HTN) or not | 47% vs. 16% | 13.1 vs. 8.1 | 85% vs. 59% | ||||
| Endostar [71] | 14 | Endostar and Temozolomide or Dacarbazine plus 5-fluorouracil | 46% | 33% vs. 50% in no therapy vs. prior therapy | Not reached | 12 | |||
| Sunitinib [64] | 26 | Sunitinib after different chemotherapy protocols | 58% | 6.0 | 1.4 | ||||
| Pazopanib [65] | 44 | Pazopanib | 24.1 | 9.5 | |||||
| Octreotide [77] | 427 | Octreotide vs. Octreotide plus Bevacizumab or interferon alfa-2b | 12% in Bevacizumab arm; 4% in interferon alfa-2b arm | No significative | 16.6 in Bevacizumab arm; 15.4 in interferon alfa-2b arm | ||||
| Pertuzumab [66] | 43 | Bevacizumab, Pertuzumab and Octreotide | 16% | 26.4 | 6.5 | ||||
| sst5TMD4 [124] | 42 | Study designed to focus on functional roles of somatostatin receptors |